


# **Disclaimer**

This presentation is prepared according to the reviewed financial statements by CPA and the financial numbers hereby are based on IFRS, please refer to the published financial statements for full content.

The presentation may contain forward-looking information and may differ materially from the actual results. DMT does not warranty as to the accuracy or completeness of such information and nor assume any undertaking further information becomes available or in light of changing circumstances. You shall not place undue reliance on any for ward looking information.

The presentation and its contents may not be reproduced to a third party without the prior written consent of DMT.







1. 公司概況(Corporate Overview)





3. 營運概況(Business Overview)



4. 財務概況(Financial Overview)



5. 策略及展望(Strategies and Outlook)



6. 行銷活動(Marketing)



7. 補充資料(Appendix)



# 1. 公司概況(Corporate Overview)

# Corporate Overview



董事長 Chairman 傅輝東 Tony Fu

# 曜亞國際

•從台灣出發、『光曜亞洲、放眼國際』


# 經營理念

•客戶滿意・快樂員工・幸福企業 ・美麗人生

# 使命

•誠信正直 團隊合作 當責創新

# **Top Provider of Medical Aesthetic Solutions in Asia**



# **DMT's Products Portfolio**



# Crate a beauty life map





Area	佳美(EB) / CYJ	Expand Business
North area	16	4
Middle area	3	0
South area	5	2
Total	24	6

### Expand Business

CYJ(台北中山)

CYJ(台北民生)

CYJ(高雄五甲)

CYJ(台北內湖)

CYJ(台北信義)

CYJ(高雄楠梓)

### 桃園市

- 桃園店
- 中壢店 Coming soon

### 新竹市

- •關新店
- 園區店

### 新竹縣

•竹北店

### 台北市

·站前店 Coming soon

•古亭店

•仁愛店

•大直店

• 士林店

- 401D
- 新莊店永和頂溪店

新北市

- •板橋店
- •蘆洲長榮店
- •新店民族店
- •林口店

### 台中市

- •河南店
- •中美店
- •站前店



### 高雄市

- •左營店
- •大順店

### 台南市

- •崇學店
- •安平店
- 永康店





### D<sub>R</sub>CYJ

全方位美學集團

□佳醫美人

全台據點豐富 / 北中南 DRCYJ健髮中心22間分店

環境舒適 / 服務親切 / 健髮纖體膚質管理





2. 市場概況(Market Overview)

### **Market Overview**

According to the Asian-Pacific Market Study issued by Medical Insight, Inc. in Mar. 2022, total Asian sales of all aesthetic products and equipment reached US\$2.7 billion in 2020 and are expected to increase by 16.4% per year through 2025.

Furthermore, medical aesthetic market can be divided into 4 sections: Energy-Based Device, Body Shaping and Skin Tightening, Dermal Filler and Neurotoxin, and DMT's distributed products covers all of the sections.





















# **Taiwan Market Overview**

New Technology

is the king

Severe competition among the Aesthetic

Industry

Channel/
Supplier
integration

Chains of Aesthetic Clinics are powerful

Intensive Marketing prevail

# **Operating Superiority**

Diversified facial injectables to satisfy comprehensive demands of aesthetic medicine market Complete aesthetic medicine consumable line, comprehensive onestop beauty treatment

The Company will continue to develop and introduce products that meet the latest and safe aesthetic medicine trends

To make facial and body treatments more comprehensive and to provide superior services to consumers, the body sculpture treatment total solution




3. 營運概況(Business Overview)


# **Business Overview**


Unit: NTD\$K

### **DMT** Revenue by product ratio



Unit: NTD\$K







# 4. 財務概況(Financial Overview)

# Consolidated Operating Revenue 1,178,195 1,009,308 1,028,183 505,701 587,686

2020

2021


2021H1


2022H1


587,686


2019

Operating Revenue 1,178,195 1,009,308 1,028,183 505,701









	2019	2020	2021	2021H1	2022H1
EPS	3.75	3.87	4.11	2.03	2.40





# 5. 策略及展望(Strategies and Outlook)

# Future Prospects




### Long-Term Planning

- Market Leader
- Southeast Asia Market
- Strategic Alliance



### Mid-Term Planning

- ✓ Preventive Medicine
- Home-Use Beauty Device
- **Body Contouring Market** Development
- **Aesthetic Consumables** 
  - **Channel Expansion**



- Launching Cosmetic Neurotoxin: Medytox
- Launching Launching Gold Ptt
- LPG/Launching Muscle Toning Device/Cooltech Promote
- DR.CYJ Brand Expansion
- Devote on Star Product Promote
- Enhance the Sales of Aesthetic Consumables























# 6. 行銷活動(Marketing)

# 曜亞國際 THE SPRING MEETING OF LMSTW O CANDELA - Medytox CVNDETV. **Medytox** AestheFill\* Fotona

### THE SPRING MEETING OF CSCSM













# **COMSULTANT'S COURSE**

### **TAIPEI**



# **TAICHUNG**



### **AMWC'S CLASSROOM ONLINE**







# 7. 補充資料(Appendix)

# **CONSOLIDATED BALANCE SHEETS-1**

Unit: NTD\$K	2020/12/31	2021/12/31	2022/6/30
Cash and cash equivalents	784,901	813,371	773,534
Debt investments with no active market - current	447,351	492,091	480,509
Notes receivable & Trade receivables	134,837	133,539	220,197
Inventories	147,124	170,233	194,810
Other current assets	22,959	33,043	48,980
Total current assets	1,537,172	1,642,277	1,718,030
Long-term investment	152,721	132,655	143,660
Property, plant and equipment	114,499	136,013	182,553
Right-of-use asset	153,364	204,793	249,225
Other non-current assets	185,079	183,053	202,301
TOTAL	2,142,835	2,298,791	2,495,769



# **CONSOLIDATED BALANCE SHEETS-2**

Unit: NTD\$K	2020/12/31	2021/12/31	2022/6/30
Notes payable & Trade payables	27,101	61,554	38,796
Other payables	152,170	134,488	260,946
contract liability	306,505	375,255	427,405
Other current liabilities	69,894	86,258	112,887
Total current liabilities	555,670	657,555	840,034
Other non-current liabilities	5,820	3,172	10,322
Lease liabilities — Non related parties	118,148	166,141	204,800
Total liabilities	679,638	826,868	1,055,156
Ordinary shares	300,000	300,000	300,000
Retained earnings	319,580	337,807	298,879
Capital surplus	627,726	627,726	627,726
Other equity	43,624	18,509	38,468
NON-CONTROLLING INTERESTS	172,267	187,881	175,540
Total equity	1,463,197	1,471,923	1,440,613
TOTAL	2,142,835	2,298,791	2,495,769
The Net Asset Value of Each Share	48.77	49.06	48.02



### CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unit: NTD\$K	2020	2021	2022.H1
	AMT	AMT	AMT
OPERATING REVENUE	1,009,308	1,028,183	587,686
OPERATING COSTS	691,266	673,601	363,010
GROSS PROFIT	318,042	354,582	224,676
GROSS PROFIT MARGIN	31.51	34.49	38.23
OPERATING EXPENSES	177,194	194,164	137,669
PROFIT FROM OPERATIONS	140,848	160,418	87,007
NON-OPERATING INCOME AND EXPENSES	7,842	13,403	7,523
PROFIT BEFORE INCOME TAX	148,690	173,821	94,530
INCOME TAX EXPENSE	32,048	32,132	21,859
NET PROFIT FOR THE YEAR	116,642	141,689	72,671
OTHER COMPREHENSIVE INCOME	(7,023)	(25,111)	19,985
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	109,619	116,578	92,656
NET PROFIT ATTRIBUTABLE TO Owners of the Company	115,995	123,206	72,072
EPS	3.87	4.11	2.40



# CONSOLIDATED STATEMENTS OF CASH FLOWS-1

Unit: NTD\$K	2020	2021	2022.H1
Cash flows from operating activities:			
Profit before tax	148,690	173,821	94,530
Total adjustments to reconcile profit	80,264	88,856	46,700
Accounts receivable	35,386	(5,416)	(94,938)
Other receivable	646	(29)	12
Inventories	63,893	(52,459)	(54,846)
Accounts payable	(31,717)	34,453	(22,758)
Other payable	(32,849)	(17,682)	2,492
Income taxes paid	(25,547)	(21,857)	(15,709)
Other	9,785	77,958	52,410
Net cash flows from operating activities	248,551	277,645	7,893

# CONSOLIDATED STATEMENTS OF CASH FLOWS-2

Unit: NTD\$K	2020	2021	2022.H1
·	2020	2021	ZUZZ•П1
Cash flows from investing activities:			
Acquisition of financial assets at amortised cost	(246,501)	(268,491)	(267,759)
Proceeds from disposal of financial assets at amortized cost	267,799	223,751	279,341
Increase in other financial assets	-	(42,277)	(46,476)
Decrease in refundable deposits	(1,890)	2,556	(3,315)
Dividends received	4,784	2,970	-
Other	(6,904)	(10,928)	(2,288)
Net cash flows from (used in) investing activities	17,288	(92,419)	(40,497)
Cash flows from financing activities:			
Cash dividends paid	(100,500)	(105,000)	-
Other	(50,943)	(43,680)	(23,722)
Net cash flows used in financing activities	(151,443)	(148,680)	(23,722)
Effect of exchange rate changes on cash and cash equivalents	(10,721)	(8,076)	16,489
Net (decrease) increase in cash and cash equivalents	103,675	28,470	(39,837)
Cash and cash equivalents at beginning of period	681,226	784,901	813,371
Cash and cash equivalents at end of period	784,901	813,371	773,534



# On the Top, Aiming High

Accumulated years of experience, DMT. is in the leading edge of the medical aesthetic market by means of sophisticated sales and marketing forces and dedicated service and management team. With successful integration, DMT has achieved vertical integration of medical aesthetics resources. From importing medical aesthetic products to assisting clinical operations, DMT has created global competitive advantage. We have already positioned ourselves in the Greater China market and will keep making all-out effort to enhance Greater China Medical Aesthetic market. The value created by DMT will be clear for all to see!



┃國際尖端醫美儀器銷售 ┃醫美儀器維修保養 ┃ 植入式填充劑銷售 ┃ 整合性醫美行銷服務 ┃ 專業健髮系統銷售 ┃

international medical aesthetics equipment selling

Medical aesthetics equipment maintenance

Dermal filler selling

Integrated marketing services for medical aesthetics